Public Sector Pension Investment Board Buys 17,254 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• The Public Sector Pension Investment Board increased its stake in Krystal Biotech, Inc. by 27.4%, owning approximately 0.28% of the company, valued at $14.47 million.
• Krystal Biotech's stock has a market cap of $4.16 billion and reported an earnings per share (EPS) of $1.29 for the latest quarter, beating estimates.
• Wall Street analysts have a consensus rating of "Buy" for Krystal Biotech, with an average price target of $210.75.

Public Sector Pension Investment Board boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 27.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,264 shares of the company's stock after purchasing an additional 17,254 shares during the period. Public Sector Pension Investment Board owned approximately 0.28% of Krystal Biotech worth $14,472,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its stake in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after purchasing an additional 105 shares during the period. GF Fund Management CO. LTD. bought a new position in Krystal Biotech in the 4th quarter worth $95,000. GAMMA Investing LLC increased its holdings in shares of Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after purchasing an additional 432 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in shares of Krystal Biotech during the 1st quarter valued at about $223,000. Finally, Avanza Fonder AB boosted its position in shares of Krystal Biotech by 66.0% during the 1st quarter. Avanza Fonder AB now owns 1,260 shares of the company's stock valued at $228,000 after acquiring an additional 501 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the transaction, the insider owned 1,508,056 shares of the company's stock, valued at approximately $226,208,400. This represents a 0.09% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 49,800 shares of company stock valued at $7,487,943 over the last quarter. 13.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a research note on Friday, July 25th. Guggenheim cut their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Citigroup reissued a "neutral" rating and issued a $166.00 price objective (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 price target on shares of Krystal Biotech in a research report on Tuesday, August 5th. Finally, Bank of America reduced their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $210.75.

Krystal Biotech Trading Down 0.0%

Krystal Biotech stock traded down $0.06 on Friday, hitting $150.27. 238,579 shares of the stock traded hands, compared to its average volume of 334,574. The firm has a market cap of $4.35 billion, a P/E ratio of 30.54 and a beta of 0.70. The business's fifty day simple moving average is $143.40 and its 200 day simple moving average is $155.01. Krystal Biotech, Inc. has a 1 year low of $122.80 and a 1 year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. The company had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).